Presence of anti-microbial antibodies in liver cirrhosis - A tell-tale sign of compromised immunity?

PLoS ONE

Volumn 5, Issue 9, 2010, Pages

  Papp, Maria ^a   Norman, Gary L ^b   Vitalis, Zsuzsanna ^a   Tornai, Istvan ^a   Altorjay, Istvan ^a   Foldi, Ildiko ^a   Udvardy, Miklos ^a   Shums, Zakera ^b   Dinya, Tamas ^a   Orosz, Peter ^c   Lombay Jr , Bela ^d   Par, Gabriella ^e   Par, Alajos ^e   Veres, Gabor ^f   Csak, Timea ^f   Osztovits, Janos ^f   Szalay, Ferenc ^f   Lakatos, Peter Laszlo ^f  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INOVA DIAGNOSTICS INC   (United States)

^c Borsod County Teaching Hospital   (Hungary)

^d Szent Ferenc Hospital   (Hungary)

^e UNIVERSITY OF PÉCS   (Hungary)

^f SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; FUNGUS ANTIBODY; OUTER MEMBRANE PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; ASCITES; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BACTERIAL TRANSLOCATION; BACTERIUM ISOLATE; CHRONIC LIVER DISEASE; COMORBIDITY; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MUCOSAL IMMUNITY; RISK FACTOR; SACCHAROMYCES CEREVISIAE; VIRUS HEPATITIS; AGED; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM; BLOOD; CASE CONTROL STUDY; FUNGUS; IMMUNOLOGY; MIDDLE AGED; MYCOSIS; PHYSIOLOGY; PROSPECTIVE STUDY;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; HEPATITIS C VIRUS; NEGIBACTERIA; POSIBACTERIA; SACCHAROMYCES CEREVISIAE;

ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIBODIES, FUNGAL; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BACTERIAL TRANSLOCATION; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; FUNGI; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; SACCHAROMYCES CEREVISIAE;

EID: 77958552727     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012957     Document Type: Article

References (54)

1. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, et al. (2001) Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 33: 41-48.
2. Tandon P, Garcia-Tsao G (2008) Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 28: 26-42.
3. Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK (2005) Infection, coagulation, and variceal bleeding in cirrhosis. Gut 54: 556-563.
4. Garcia-Tsao G, Wiest R (2004) Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 18: 353-372.
5. Yoshida H, Hamada T, Inuzuka S, Ueno T, Sata M, et al. (1993) Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. Am J Gastroenterol 88: 2067-2071.
6. Caly WR, Strauss E (1993) A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 18: 353-358.
7. Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, et al. (1999) Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 29: 1655-1661.
8. Soares-Weiser K, Brezis M, Tur-Kaspa R, Leibovici L (2002) Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev CD002907.
9. Wiest R, Garcia-Tsao G (2005) Bacterial translocation (BT) in cirrhosis. Hepatology 41: 422-433.
10. Saab S, Hernandez JC, Chi AC, Tong MJ (2009) Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 104: 993-1001.
11. Albillos A, de la Hera A, González M, Moya JL, Calleja JL, et al. (2003) Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 37: 208-217.
12. Albillos A, Hera Ad Ade L, Reyes E, Monserrat J, Muñoz L, et al. (2004) Tumour necrosis factor-alpha expression by activated monocytes and altered Tcell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol 40: 624-631.
13. Singh N, Wagener MM, Gayowski T (2003) Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clin Microbiol Infect 9: 531-537.
14. Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, et al. (2007) Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133: 818-824.
15. Zapater P, Francés R, González-Navajas JM, de la Hoz MA, Moreu R, et al. (2008) Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 48: 1924-1931.
16. Papp M, Foldi I, Altorjay I, Palyu E, Udvardy M, et al. (2009) Anti-microbial antibodies in celiac disease: trick or treat? World J Gastroenterol 15: 3891-3900.
17. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, et al. (2004) Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126: 414-424.
18. Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, et al. (2007) Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis 13: 984-992.
19. Toumi D, Mankai A, Belhadj R, Ghedira-Besbes L, Jeddi M, et al. (2007) Anti- Saccharomyces cerevisiae antibodies in coeliac disease. Scand J Gastroenterol 42: 821-826.
20. Granito A, Muratori L, Muratori P, Guidi M, Lenzi M, et al. (2006) Antisaccharomyces cerevisiae antibodies (ASCA) in coeliac disease. Gut 55: 296.
21. Hill PG, Holmes GK (2008) Coeliac disease: a biopsy is not always necessary for diagnosis. Aliment Pharmacol Ther 27: 572-577.
22. Saitoh O, Sugi K, Lojima K, Matsumoto H, Nakagawa K, et al. (1999) Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World J Gastroenterol 5: 391-396.
23. De Palma GD, Rega M, Masone S, Persico F, Siciliano S, et al. (2005) Mucosal abnormalities of the small bowel in patients with cirrhosis and portal hypertension: a capsule endoscopy study. Gastrointest Endosc 62: 529-534.
24. Bhonchal S, Nain CK, Prasad KK, Nada R, Sharma AK, et al. (2008) Functional and morphological alterations in small intestine mucosa of chronic alcoholics. J Gastroenterol Hepatol 23: e43-48.
25. Yagmur E, Schnyder B, Scholten D, Schirin-Sokhan R, Koch A, et al. (2006) [Elevated concentrations of fecal calprotectin in patients with liver cirrhosis]. Dtsch Med Wochenschr 131: 1930-1934.
26. Kaplan MM, Gershwin ME (2005) Primary biliary cirrhosis. N Engl J Med 353: 1261-1273.
27. Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP (2008) The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 48(Suppl 1): S38-57.
28. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, et al. (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31: 929-938.
29. Durand F, Valla D (2005) Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 42: S100-107.
30. Kamath PS, Kim WR (2007) The model for end-stage liver disease (MELD). Hepatology 45: 797-805.
31. Muratori P, Muratori L, Guidi M, Maccariello S, Pappas G, et al. (2003) Anti- Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol 132: 473-476.
32. Reddy KR, Colombel JF, Poulain D, Krawitt EL (2001) Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease. Am J Gastroenterol 96: 252-253.
33. Sakly W, Jeddi M, Ghedira I (2008) Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis. Dig Dis Sci 53: 1983-1987.
34. Papp M, Norman GL, Altorjay I, Lakatos PL (2007) Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol 13: 2028-2036.
35. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, et al. (2001) Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 34: 32-37.
36. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB (1995) Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 108: 1835-1841.
37. Guarner C, Soriano G (2005) Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 17: 27-31.
38. Norman K, Pirlich M (2008) Gastrointestinal tract in liver disease: which organ is sick? Curr Opin Clin Nutr Metab Care 11: 613-619.
39. Bauer TM, Steinbrückner B, Brinkmann FE, Ditzen AK, Schwacha H, et al. (2001) Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 96: 2962-2967.
40. Casafont Morencos F, de las Heras Castaño G, Martín Ramos L, López Arias MJ, Ledesma F, et al. (1996) Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 41: 552-556.
41. Gunnarsdottir SA, Sadik R, Shev S, Simrén M, Sjövall H, et al. (2003) Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 98: 1362-1370.
42. Balzan S, de Almeida Quadros C, de Cleva R, Zilberstein B, Cecconello I (2007) Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol 22: 464-471.
43. Mehta A, Loarca L, Long RE, Comunale M, Block TM (2009) Discovery of an antibody in patients with liver disease that promotes bacterial growth and is associated with markers of endtoxin exposure. AASLD MON-A. 1089 p.
44. Pohl J, Ring A, Stremmel W, Stiehl A (2006) The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 18: 69-74.
45. Vermeire S, Vermeulen N, Van Assche G, Bossuyt X, Rutgeerts P (2008) (Auto)antibodies in inflammatory bowel diseases. Gastroenterol Clin North Am 37: 429-438.
46. Henckaerts L, Pierik M, Joossens M, Ferrante M, Rutgeerts P, et al. (2007) Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 56: 1536-1542.
47. Mei L, Targan SR, Landers CJ, Dutridge D, Ippoliti A, et al. (2006) Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 130: 1078-1085.
48. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, et al. (2008) New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 103: 665-681.
49. Lakatos PL, Willheim-Polli C, Folhoffer A (2004) NOD2/CARD15 SNP8, 12 and 13 and other exon4 mutations and primary biliary cirrhosis in Hungarian and Polish patients. Z Gastroenterol 42: 423.
50. Gaj P, Habior A, Mikula M, Otrowski J (2008) Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for Crohn's disease in Polish patients. BMC Med Genet 9: 81.
51. Albillos A, de-la-Hera A, Alvarez-Mon M (2004) Serum lipopolysaccharidebinding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 363: 1608-1610.
52. Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, et al. (2010) Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 51: 1327-1333.
53. Altorjay I, Vitalis Zs, Tornai I, Palatka K, Kacska S, et al. (2010) Mannosebinding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis. J Hepatol; June 2?Epub ahead of print?
54. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, et al. (2010) Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis; 16: 263-274.